



AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph at page 16, lines 26-32, as follows:

The compositions containing the present adenoviruses or cocktails thereof can be administered for prophylactic and/or therapeutic treatments of neoplastic disease. In therapeutic application, compositions are administered to a patient already affected by the particular neoplastic disease, in an amount sufficient to cure or at least partially arrest the condition and its complications. An amount adequate to accomplish this is defined as a "therapeutically effective dose" or "efficacious dose." Amounts effective for this use will depend upon the severity of the condition, the general state of the patient, the route of administration and the potency of the virus.?

Please amend Table 2 on page 18 by adding the SEQ ID NO column, as follows:

Table 2.

Virus	Mutation	Primer sequences	SEQ ID NO:
ONYX-051	R240A	GTTATTATGAATGTAGCGTTACTGGCCCC	<u>1</u>
		GGGGCCAGTAAACGCTACATTATAAAC	<u>2</u>
ONYX-052	T255A	GTTCCTGGCCAATGCCAACCTTATCCTACAC	<u>3</u>
		GTGTAGGATAAGGTTGGCATTGCCAGGAAAAC	<u>4</u>
ONYX-053	H260A	CCAACCTTATCCTAGCCGGTGAAGCTTC	<u>5</u>
		GAAGCTTACACCCGGTAGGATAAGGTTGG	<u>6</u>
ONYX-054	C271A	GGGTTAACAAATACCGCCGTGGAAGCCTGG	<u>7</u>
		CCAGGCTCCACGGCGGTATTGTTAACCC	<u>8</u>
ONYX-056	R281A	CGATGTAAGGGTTGGGGCTGTGCCTTTAC	<u>9</u>
		GTAAAAGGCACAGCCCCGAAACCTTACATCG	<u>10</u>
ONYX-057	G282A	GTAAGGGTTGGGCCTGTGCCTTTAC	<u>11</u>
		GTAAAAGGCACAGGCCGAACCTTAC	<u>12</u>
ONYX-058	A284A	GTAAGGGTTGGGGCTTACTGCTGCTGGAAGG	<u>13</u>
		CCTTCCAGCAGCAGTAAAGGAAACAGCCCCGAACCTTAC	<u>14</u>
ONYX-059	F285L	GGTCGGGGCTGTGCCTTAACTGCTGCTGGAAGGGGG	<u>15</u>
		CCCCTCCAGCAGCAGTAAAGGCACAGCCCCGAACC	<u>16</u>
ONYX-060	C288A	GGGCTGTGCCTTTACTGCGCCTGGAAGGGGGTGGTG	<u>17</u>
		CACACCAACCCCTCCAGGCGCAGTAAAGGCACAGCCC	<u>18</u>
ONYX-061	W289F	GCTGTGCCTTTACTGCTGCTTAAAGGGGGTGGTGTGCG	<u>19</u>
		GCGACACACCACCCCTAAAGCAGCAGTAAAGGCACAGC	<u>20</u>
ONYX-062	W289A	GCTGTGCCTTTACTGCTGCGGAAGGGGGTGGTGTGCG	<u>21</u>
		CGACACACCACCCCTCGCGCAGCAGTAAAGGCACAGC	<u>22</u>

ONYX-063	K290A	CTGCTGGCGGGGTGGT CACCACCCCGCCAGCAGCAG	<u>23</u> <u>24</u>
ONYX-064	R295A	TGGAAGGGGGTGGTGTGCCCCAAAAGCAGGGCTTC GAAGCCCTGCTTTGGGGCACACACCACCCCTTCCA	<u>25</u> <u>26</u>
ONYX-065	K297A	GGTGGTGTGTCGCCCCGCAAGCAGGGCTCAATTAAAGAAATG CATTCTTAATTGAAGCCCTGCTTGCAGGGCGACACACCACC	<u>27</u> <u>28</u>
ONYX-066	K303A	CCAAAAGCAGGGCTCAATTGCGAAATGCCTCTTGAAAGGT G CACCTTCAAAGAGGCATTGCAATTGAAGCCCTGCTTTGG	<u>29</u> <u>30</u>
ONYX-067	E308A	CTTCAATTAAAGAAATGCCTCTTGCAAGGTGTACCTGGTAT CC GGATACCCAAGGTACACCTGCAAAGAGGCATTCTTAATTG AAG	<u>31</u> <u>32</u>

Please amend Table 2 (cont.) on page 19 by adding the SEQ ID NO column, as follows:

ONYX-068	R309A	TCAATTAAAGAAATGCCTCTTGAGCGTGTACCTGGTATCC TGTC GACAGGATAACCAAGGTACACGCTCAAAGAGGCATTCTTA ATTGA	<u>33</u> <u>34</u>
ONYX-069	E317A	TACCTTGGGTATCCTGTCTGGGGTAACCTCAGGGTGCG CGCACCTGGAGTTACCCGAGACAGGATAACCAAGGTA	<u>35</u> <u>36</u>
ONYX-070	G318A*	TACCTTGGGTATCCTGTCTGAGGCTACCTCAGGGTCCGCC GGCGGACCCCTGGAGGTAGCCTCAGACAGGATAACCAAGGTA	<u>37</u> <u>38</u>
ONYX-071	G318A-N	TACCTTGGGTATCCTGTCTGAGGCTAACCTCAGGGTGCGCC GGCGCACCCCTGGAGTTAGCCTCAGACAGGATAACCAAGGTA	<u>39</u> <u>40</u>
ONYX-080	E421A	CTAAGATATTGCTTGAGCCGGCGAGCATGTCCAAGGTGAAC GTTCACCTTGGACATGCTGCCGGCTAAGCAATATCTTAG	<u>41</u> <u>42</u>
ONYX-081	K425A	GAGCCCGAGAGCATGTCCCGGGTAACCTGAACGGGG CCCCGTTCAGGTTACCGCGGACATGCTCTCGGGCTC	<u>43</u> <u>44</u>
ONYX-082	D433A	GAACCTGAACGGGGTGGTGCATGACCATGAAGATCTGG CCAGATCTTCATGGTCATGGCAAACACCCCGTTAGGTTTC	<u>45</u> <u>46</u>
ONYX-083	K440A	CCATGAAGATCTGGCGGTGCTGAGGTAC GTACCTCAGCACCGCCCAGATCTTCATGG	<u>47</u> <u>48</u>
ONYX-084	R443A	GGAAGGTGCTGGCGTACGATGAGACC GGTCTCATCGTACGCCAGCACCTTCC	<u>49</u> <u>50</u>
ONYX-085	Y444A	GGAAGGTGCTGAGGGCCGATGAGACCCGC GCGGGTCTCATCGGCCCTCAGCACCTTCC	<u>51</u> <u>52</u>

Table 2, continued

* Onyx-070 had two amino acids changed: Gly 318 to Ala, and Asn 319 to Thr.